NAVB
Income statement / Annual
Last year (2022), Navidea Biopharmaceuticals, Inc.'s total revenue was $65,652.00,
a decrease of 87.65% from the previous year.
In 2022, Navidea Biopharmaceuticals, Inc.'s net income was -$15.18 M.
See Navidea Biopharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$65,652.00
|
$531,513.00
|
$915,013.00
|
$26,618.00
|
$322,521.00
|
$1.81 M
|
$21.97 M
|
$13.25 M
|
$6.27 M
|
$1.13 M
|
| Cost of Revenue |
$184,947.00 |
$198,834.00 |
$1,048.00 |
$6,667.00 |
$96,636.00 |
$3,651.00 |
$2.30 M |
$1.75 M |
$1.59 M |
$332,815.00 |
| Gross Profit |
-$119,295.00 |
$332,679.00 |
$913,965.00 |
$19,951.00 |
$225,885.00 |
$1.81 M |
$19.67 M |
$11.49 M |
$4.69 M |
$797,815.00 |
| Gross Profit Ratio |
-1.82 |
0.63 |
1 |
0.75 |
0.7 |
1 |
0.9 |
0.87 |
0.75 |
0.71 |
| Research and Development
Expenses |
$5.97 M
|
$5.14 M
|
$4.93 M
|
$5.34 M
|
$4.22 M
|
$4.51 M
|
$8.88 M
|
$12.79 M
|
$16.78 M
|
$23.71 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$7.96 M
|
$7.45 M
|
$6.69 M
|
$6.28 M
|
$7.70 M
|
$11.17 M
|
$13.01 M
|
$17.26 M
|
$15.54 M
|
$15.53 M
|
| Other Expenses |
$0.00 |
-$14,115.00 |
-$21,855.00 |
-$631,208.00 |
$1,145.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$13.93 M |
$12.59 M |
$11.63 M |
$10.98 M |
$11.07 M |
$15.68 M |
$21.90 M |
$30.05 M |
$32.32 M |
$39.24 M |
| Cost And Expenses |
$14.12 M |
$12.59 M |
$11.63 M |
$10.99 M |
$11.17 M |
$15.69 M |
$24.19 M |
$31.80 M |
$33.91 M |
$39.57 M |
| Interest Income |
$0.00 |
$6,000.00 |
$11,344.00 |
$25,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$16,102.00 |
$18,838.00 |
| Interest Expense |
$1.10 M |
$6,361.00 |
$0.00 |
$25,288.00 |
$30,799.00 |
$168,971.00 |
$4,866.00 |
$1.27 M |
$3.71 M |
$2.78 M |
| Depreciation &
Amortization |
$95,819.00
|
$198,834.00
|
$190,579.00
|
$144,512.00
|
$150,385.00
|
$254,587.00
|
$501,368.00
|
$571,419.00
|
$500,183.00
|
$404,181.00
|
| EBITDA |
-$13.88 M
|
-$11.51 M
|
-$10.64 M
|
-$10.82 M
|
-$10.85 M
|
-$13.14 M
|
-$6.87 M
|
-$21.31 M
|
-$31.52 M
|
-$38.03 M
|
| EBITDA Ratio |
-211.34 |
-23.38 |
-11.71 |
-411.85 |
-17.23 |
-5.41 |
-0.21 |
-1.15 |
-4.49 |
-34 |
| Operating Income Ratio
|
-214.02
|
-22.69
|
-11.71
|
-411.85
|
-33.63
|
-7.67
|
-0.1
|
-1.4
|
-4.4
|
-34
|
| Total Other
Income/Expenses Net |
-$1.13 M
|
$345,524.00
|
-$10,510.00
|
$17,675.00
|
-$5.32 M
|
-$3.91 M
|
$2.77 M
|
-$10.32 M
|
-$13.14 M
|
-$4.26 M
|
| Income Before Tax |
-$15.18 M |
-$11.71 M |
-$10.72 M |
-$10.94 M |
-$16.17 M |
-$17.79 M |
-$14.31 M |
-$28.76 M |
-$35.73 M |
-$42.70 M |
| Income Before Tax Ratio
|
-231.18
|
-22.04
|
-11.72
|
-411.18
|
-50.13
|
-9.83
|
-0.65
|
-2.17
|
-5.69
|
-37.77
|
| Income Tax Expense |
$0.00 |
$16,043.00 |
-$81,737.00 |
$707.00 |
$2,747.00 |
-$4.06 M |
-$648,000.00 |
-$436,051.00 |
$2.68 M |
$2.37 M |
| Net Income |
-$15.18 M |
-$11.73 M |
-$10.64 M |
-$10.95 M |
-$16.13 M |
$74.95 M |
-$14.31 M |
-$27.56 M |
-$35.73 M |
-$42.70 M |
| Net Income Ratio |
-231.18 |
-22.07 |
-11.63 |
-411.21 |
-50 |
41.4 |
-0.65 |
-2.08 |
-5.69 |
-37.77 |
| EPS |
-0.59 |
-0.4 |
-0.45 |
-0.76 |
-1.89 |
9.4 |
-1.84 |
-3.65 |
-4.8 |
-7.01 |
| EPS Diluted |
-0.56 |
-0.4 |
-0.45 |
-0.76 |
-1.89 |
9 |
-1.84 |
-3.65 |
-4.8 |
-7.01 |
| Weighted Average Shares
Out |
$29.34 M
|
$29.34 M
|
$23.90 M
|
$14.39 M
|
$8.53 M
|
$8.08 M
|
$7.77 M
|
$7.56 M
|
$7.44 M
|
$6.09 M
|
| Weighted Average Shares
Out Diluted |
$30.90 M
|
$29.34 M
|
$23.90 M
|
$14.39 M
|
$8.53 M
|
$8.30 M
|
$7.77 M
|
$7.56 M
|
$7.44 M
|
$6.09 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
